Bristol Myers Squibb Treatment Shows Improvement in Alzheimer's Hallucinations, Delusions
By Kelly Cloonan
Bristol Myers Squibb said its KarXT treatment demonstrated improvements in scores of hallucinations and delusions, as well as overall disease severity, in Alzheimer's patients in a recent study.
The company said Wednesday the preliminary data from the Phase 3 study, as well as findings regarding the treatment's long-term safety and tolerability from another study, are encouraging as it waits for full results.
In the safety-focused study, KarXT was generally well tolerated through week 52, with low rates of discontinuation. Treatment-emergent adverse events (TEAEs) occurred in 65% of participants, and serious TEAEs occurred in 7.7% of participants, the company said.
Alzheimer's disease is the most common type of dementia in adults. About 30% to 50% of Alzheimer's patients experience symptoms such as hallucinations and delusions, called psychosis, over the course of the disease.
Write to Kelly Cloonan at kelly.cloonan@wsj.com
(END) Dow Jones Newswires
November 18, 2026 09:57 ET (14:57 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular

5 Stocks to Buy After Earnings

7 Undervalued Stocks That Crushed Earnings

This Newly Undervalued Stock Has Plenty of Growth Ahead

Are These Riskier Bond ETFs Worth the Higher Yields?

